Data From INNOVIVE Pharmaceuticals' Oncology Drug Programs to Be Presented at the American Society of Hematology 48th Annual Mee
07 December 2006 - 12:00AM
PR Newswire (US)
NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- INNOVIVE
Pharmaceuticals, Inc. (OTC:IVPH) (BULLETIN BOARD: IVPH) announced
that data supporting further development of the company's drug
candidates INNO-406, an orally bioavailable dual Bcr-Abl and
Lyn-kinase inhibitor for Gleevec resistant chronic myelogenous
leukemia, and INNO-305, a peptide immunotherapy for the treatment
of acute myelogenous leukemia, will be presented at the American
Society of Hematology (ASH) 48th Annual Meeting and Exposition. The
conference takes place December 9-12, 2006 at the Orange County
Convention Center in Orlando, Florida. INNO-406 * Abstract #834:
"Cyclosporin A, a P-gp Inhibitor, Augments the Anti-Central Nervous
System Ph+ Leukemia Effects of INNO-406." Oral Presentation: Dec.
12 at 8:15am EST; Room 315 * Abstract #2178: "BH3 Mimetic Augments
the Induction of Apoptosis by INNO-406, a Novel Bcr-Abl/Lyn
Inhibitor, in Bcr-Abl+ Leukemic Cells." Poster Presentation: Dec.
10 from 9:00am to 8:00pm EST; Hall E1, Board 356-II * Abstract
#2177: "Cell Death Mechanisms Induced by INNO-406, a Novel Tyrosine
Kinase Inhibitor for Imatinib-Resistant Ph+ Leukemia." Poster
Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board
355-II * Abstract #2123: "CXCR4 Up-Regulation by Imatinib Mesylate
Induces CML Cell Migration to Bone Marrow Stroma and Promotes
Survival of Chemoresistant Quiescent CML Cells." Poster
Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board
301-II * Abstract #2167: "Centrosome Aberrations, Disturbed Mitotic
Spindle Formation and G1 Arrest in Normal and Leukemic Cells
Treated with the SRC/ABL Inhibitor Dasatinib." Poster Presentation:
Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board 345-II * Abstract
#2179: "The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation
and Survival of Mouse Cells Expressing Several Imatinib Mesylate
Resistant Bcr/Abl Mutants and Cells from CML Patients." Poster
Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board
357-II INNO-305 * Abstract #3706: "CD4+ Peptide Epitopes from the
WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and
Kill Leukemia and Solid Tumor Cells." Poster Presentation: Dec. 11
from 10:30am to 7:00pm EST; Hall E1, Board 935-III About INNO-406
INNO-406 (formerly known as NS-187) is an orally bioavailable,
rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor
currently in Phase I clinical studies. According to a study
published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55
times more potent than imatinib in vitro, and at least 10 times as
effective as imatinib mesylate in suppressing the growth of Bcr-Abl
bearing tumors. INNO-406 has demonstrated activity in 12 of 13
imatinib-resistant cell lines. In addition to its Bcr-Abl
inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation
of Lyn kinase activity is a well recognized cause of imatinib
resistance. Lyn kinase activation has also been documented in a
variety of solid tumors, including prostate cancer. About INNO-305
INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is
in a Phase I clinical trial for the treatment of patients with
acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)
as well as patients with non-small cell lung cancer (NSCLC) and
mesothelioma. INNO-305 is unique among WT1 peptide cancer
immunotherapeutics because of its ability to stimulate both CD8 and
CD4 T-cells. It is believed that stimulating both types of T-cells
may result in a more robust and ubiquitous immune response. About
Innovive Pharmaceuticals INNOVIVE Pharmaceuticals, Inc. acquires,
develops and commercializes novel therapeutics addressing
significant unmet medical needs in the fields of oncology and
hematology. The company has three drug programs in clinical
development, INNO-406, INNO-206, and INNO-305, for the treatment of
chronic myelogenous leukemia, small cell lung cancer, and acute
myelogenous leukemia. For additional information visit
http://www.innovivepharma.com/. DATASOURCE: INNOVIVE
Pharmaceuticals, Inc. CONTACT: Steve Kelly, President and CEO of
INNOVIVE Pharmaceuticals, Inc., +1-212-716-1820; or Rachel Lipsitz,
Media & Investor Relations, Porter Novelli Life Sciences,
+1-619-849-5378, for INNOVIVE Pharmaceuticals, Inc. Web site:
http://www.innovivepharma.com/
Copyright